Mereo BioPharma Group PLC ADR logo

Mereo BioPharma Group PLC ADR(MREO)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.31
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for MREO

11/13/2026: MREO (1-star) is currently NOT-A-BUY. Pass it for now.

Mereo BioPharma is a clinical-stage biotechnology company that builds its value by acquiring and developing late-stage therapies for rare diseases. The company is primarily known for its lean operating model and strategic focus on lead assets like Setrusumab, which has reached pivotal Phase 3 testing. While this approach offers investors significant growth potential, it remains subject to high binary risks associated with clinical trial outcomes and regulatory hurdles. The stock is best suited for growth-oriented investors who can tolerate substantial volatility. Investors should monitor upcoming clinical readouts and partnership updates, as these remain the most critical drivers of the company's long-term valuation and future potential.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers high growth potential linked to clinical success but carries substantial binary risk.
Momentum investorStrong fit while signal remains positiveMomentum investors may favor the stock during positive clinical data releases or partnership announcements.
Value investorWeak fitThe lack of earnings and reliance on speculative R&D makes it a poor fit for traditional value strategies.
Dividend investorWeak fitThe company does not pay a dividend and requires significant capital for development.
Low-risk investorWeak fitHigh clinical, financial, and price volatility makes this unsuitable for low-risk portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock is highly sensitive to news regarding clinical trial outcomes.
Valuation riskHighValuation is speculative and heavily dependent on the net present value of late-stage assets.
Competition riskHighEstablished players can outspend and out-market smaller firms if they enter similar therapeutic spaces.
Business qualityMediumThe company relies on its ability to license and effectively manage outsourced drug development.
Dividend incomeLow / noneInvestors should not expect income from this investment.
Execution riskHighThe company must successfully navigate complex regulatory and clinical paths to reach the market.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 49.11M USD
Price to earnings Ratio -
1Y Target Price 1.96
Price to earnings Ratio -
1Y Target Price 1.96
Volume (30-day avg) 829.6K shares
Beta 0.2
52 Weeks Range 0.20 - 2.37
Updated Date 11/13/2026
52 Weeks Range 0.20 - 2.37
Updated Date 11/13/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.15

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit -89.13%
Avg. Invested days 31
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
MREO receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
MREO has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and moderate ownership. In FY2025 versus FY2024, moderate earnings growth (+3.2%) is partially offset by weak cash generation (FCF margin -6198.2%), slightly negative revenue growth (+0.0%), weak profitability (net margin -8375.6%).

Financial Health Rating

★★★★★
MREO's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 88.7%). Cash strength is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is MREO's strongest growth driver at +7.6% FY2025 versus FY2024 (moderate, 3 stars). By comparison, while revenue growth (+0.0%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 32.9% (moderate) and 78.3% of outstanding shares are publicly tradable (solid). Insider ownership is only 0.75%, which materially reduces the ownership score.

Top 5 Institutional Investors

Rubric Capital Management LP 9.59%
Bank of America Corp 5.13%
Defilade Capital Management, L.P. 4.73%
Newtyn Management LLC 1.88%
Tejara Capital Ltd 1.28%

Unit Economics (Per $1K Revenue)

★★★★★
MREO generates approximately $734 of gross profit, $-76,514 of operating income, and $-61,982 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 2-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 4.43%

Quantitative Style Profile

★★★★★
MREO has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Rare Disease TherapeuticsClinical-stage candidates like Setrusumab and Alvelestat.The company makes money by developing drugs to the point where they are licensed or sold to larger pharmaceutical companies or commercialized.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 23.19M
Price to Sales(TTM) 61.38
Enterprise Value 23.19M
Price to Sales(TTM) 61.38
Enterprise Value to Revenue 28.98
Enterprise Value to EBITDA -1.21
Shares Outstanding 159.70M
Shares Floating 125.03M
Shares Outstanding 159.70M
Shares Floating 125.03M
Percent Insiders 0.75
Percent Institutions 32.89

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.